(Q35103628)

6 August 2017

1 reference

title

Health care economic analyses and value-based medicine (English)

1 reference

6 August 2017

Melissa M Brown

1

1 reference

6 August 2017

Gary C Brown

series ordinal

2

1 reference

6 August 2017

Sanjay Sharma

series ordinal

3

1 reference

6 August 2017

Jennifer Landy

series ordinal

4

1 reference

6 August 2017

language of work or name

1 reference

1 March 2003

1 reference

6 August 2017

published in

Survey of Ophthalmology

1 reference

6 August 2017

volume

48

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

204-223

1 reference

Evidence-based medicine. A new approach to teaching the practice of medicine

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

EuroQol--a new facility for the measurement of health-related quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part I-methods

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Cross-cultural differences in the reporting of global functional capacity: an example in cataract patients

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Test-retest performance of a mailed version of the Medical Outcomes Study 36-Item Short-Form Health Survey among older adults

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Comparing the performance of health status measures for healthy older adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Using economic evaluations to make formulary coverage decisions. So much for guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Using Pharmacoeconomic Analysis to Make Drug Insurance Coverage Decisions

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Existence of an Equilibrium for a Competitive Economy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Efficacy of anterior chamber paracentesis and Carbogen in treating acute nonarteritic central retinal artery occlusion

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

The effectiveness of cost-effectiveness analysis in containing costs

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

The Sickness Impact Profile: Development and Final Revision of a Health Status Measure

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

A brief introduction to Monte Carlo simulation

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Managing pharmaceutical expenditure while increasing access. The pharmaceutical management agency (PHARMAC) experience

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

The death of cost-minimization analysis?

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

A fair approach to discounting future effects: taking a societal perspective.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Patient and informal caregiver time in cost-effectiveness analysis. A response to the recommendations of the Washington Panel.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Cost-utility analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Patient perceptions of quality-of-life associated with bilateral visual loss.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Quality of life associated with diabetes mellitus in an adult population.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Incremental cost effectiveness of laser photocoagulation for subfoveal choroidal neovascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Incremental cost-effectiveness of laser therapy for visual loss secondary to branch retinal vein occlusion

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Incremental cost-effectiveness of laser therapy for choroidal neovascularization associated with histoplasmosis

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

A cost-utility analysis of interventions for severe proliferative vitreoretinopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Cost-effectiveness of treatment for threshold retinopathy of prematurity

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Utility values and age-related macular degeneration.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Outcome of corneal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Utility values associated with blindness in an adult population

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

A utility analysis correlation with visual acuity: methodologies and vision in the better and poorer eyes

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Quality of life associated with unilateral and bilateral good vision

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Evidence-based medicine, utilities, and quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Utility values and diabetic retinopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Incremental cost-effectiveness of initial cataract surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Reproducibility and Responsiveness of the VF-14

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Comparison of the results of first and second cataract eye surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

A comprehensive league table of cost-utility ratios and a sub-table of "panel-worthy" studies

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Cost-utility analysis of the cochlear implant in children.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Visual function among corneal disease patients waiting for penetrating keratoplasty in British Columbia

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Measuring visual symptoms in British cataract patients: the cataract symptom scale

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Cost effectiveness of a single-function treatment center for cataract surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Primer on medical decision analysis: Part 1--Getting started.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Primer on Medical Decision Analysis: Part 2—Building a Tree

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Time preference, duration and health state valuations

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Cost-utility analysis of living-donor kidney transplantation followed by pancreas transplantation versus simultaneous pancreas-kidney transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Systematic overview of cost-utility assessments in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

The value of screening for glaucoma with tonometry

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

A comparison of three health status measures in primary care outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

The cost-effectiveness of preventing AIDS-related opportunistic infections

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Methodology for measuring health-state preferences--II: Scaling methods

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Cost-utility in practice: a policy maker's guide to the state of the art.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

A tool to improve quality of reporting published economic analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Raising the quality of cost-utility analyses: lessons learnt and still to learn

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Influence of glaucomatous visual field loss on health-related quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Discounting life-years: whither time preference?

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

The SF-36 health survey questionnaire: is it suitable for use with older adults?

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Cost-effectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

What is heartburn worth? A cost-utility analysis of management strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Costs of illness in cost-effectiveness analysis. A review of the methodology

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Patients' utilities for cancer treatments: a study of the chained procedure for the standard gamble and time tradeoff.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Cost-effectiveness of detecting and treating diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Detecting and treating retinopathy in patients with type I diabetes mellitus. A health policy model

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

A note on the depreciation of the societal perspective in economic evaluation of health care

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Incorporating future costs in medical cost-effectiveness analysis: implications for the cost-effectiveness of the treatment of hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Cost-utility analysis from a societal perspective.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Cost utility analysis of maintenance treatment for recurrent depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

The Quality of Well-Being Scale: critical similarities and differences with SF-36.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Incorporating patients' preferences into medical decisions

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Screening for prostate cancer. A decision analytic view

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Primer on medical decision analysis: Part 4--Analyzing the model and interpreting the results

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Symptom severity and patients' values in the decision to perform a transurethral resection of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

The effect of elective total hip replacement on health-related quality of life.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

A study of the quality of life and cost-utility of renal transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

The Glaucoma Symptom Scale. A brief index of glaucoma-specific symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Implications of decision analysis for ophthalmic practice

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Validity of the visual function index (VF-14) in patients with retinal disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Where are the economic guidelines coming from?

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Quality of life of patients with ulcerative colitis preoperatively and postoperatively

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Medical Outcomes Study Short Form 36: a possible source of utilities?

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Accounting for future costs in medical cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Effect of future costs on cost-effectiveness of medical interventions among young adults: the example of intensive therapy for type 1 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Inconsistencies in the "Societal Perspective" on Costs of the Panel on Cost-Effectiveness in Health and Medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Cost-utility analysis of prophylactic treatment with oral ganciclovir for cytomegalovirus retinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

The cost-effectiveness of magnetic resonance imaging for patients with equivocal neurological symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Primer on Medical Decision Analysis: Part 3—Estimating Probabilities and Utilities

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Primer on Medical Decision Analysis: Part 5—Working with Markov Processes

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Are pharmaceuticals cost-effective? A review of the evidence.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Are methods for estimating QALYs in cost-effectiveness analyses improving?

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

The U.K. NHS economic evaluation database. Economic issues in evaluations of health technology

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Is the SF-36 suitable for assessing health status of older stroke patients?

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Production gains from health care: what should be included in cost-effectiveness analyses?

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Physicians' assessments of the utility of health states associated with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Visual function and quality of life among patients with glaucoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Health and economic benefits of increased beta-blocker use following myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Utility Functions for Life Years and Health Status

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Preferences for health outcomes. Comparison of assessment methods

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Users' guides to the medical literature. VII. How to use a clinical decision analysis. A. Are the results of the study valid? Evidence-Based Medicine Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Quality of life in myopia

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Is the societal perspective in cost-effectiveness analysis useful for decision makers?

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Utilities for major stroke: results from a survey of preferences among persons at increased risk for stroke.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Screening for diabetic retinopathy: a relative cost-effectiveness analysis of alternative modalities and strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Validity of the time trade-off and standard gamble methods of utility assessment in retinal patients

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Converting visual acuity to utilities

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

The cost-effectiveness of grid laser photocoagulation for the treatment of diabetic macular edema: results of a patient-based cost-utility analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

The cost-effectiveness of early vitrectomy for the treatment of vitreous hemorrhage in diabetic retinopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Understanding cost effectiveness: a detailed review

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Antiviral therapies for herpes zoster infections. Are they economically justifiable?

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Markov models in medical decision making: a practical guide.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

1 reference

7 January 2021

Measuring costs in cost-utility analyses. Variations in the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Cost-utility analyses of clinical preventive services: published ratios, 1976-1997.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Five‐Hundred Life‐Saving Interventions and Their Cost‐Effectiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Functional status versus utilities in survivors of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

The cost-utility of screening for depression in primary care.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Discounting costs and effects: a reconsideration

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

A comparison of three quality of life instruments in subjects with angina pectoris: the Sickness Impact Profile, the Nottingham Health Profile, and the Quality of Well Being Scale.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Explaining distortions in utility elicitation through the rank-dependent model for risky choices.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Foundations of Cost-Effectiveness Analysis for Health and Medical Practices

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Computer-assisted decision analysis in orthopedics: resurfacing the patella in total knee arthroplasty as an example

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Cost-benefit analyses in the health-care literature: don't judge a study by its label

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

Cost effectiveness of current approaches to the control of retinopathy in type I diabetics

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

The MOS short-form general health survey. Reliability and validity in a patient population

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900457-5

7 January 2021

10.1016/S0039-6257(02)00457-5

Identifiers

DOI

1 reference

release_ylhfnk7yt5e2fk477ph6zxfxvi

6 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ylhfnk7yt5e2fk477ph6zxfxvi

24 November 2022

mapped directly with Wikidata item

1 reference